TickerGuard
Buy Day today: Neutral (52) Mixed market breadth · no major macro event
KZIA

Kazia Therapeutics Ltd

Healthcare · Biotechnology

6.60$ -5.1% vs. previous close Closing price · As of: Nov 13, 2026

Ownership

Ownership Structure

Who owns Kazia Therapeutics Ltd (KZIA)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 82.2% of the shares are freely tradable; institutional investors hold 30.8%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 30.8%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 19.8%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 82.2%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 9.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 11Mio.

Largest Shareholders

Institutions

Institutions KZIA
Name Stake (%) Shares Change (%) Date
Boxer Capital Management, LLC 4.33 560,000 +0.0 06/30/2026
F.L.Putnam Investment Management 3.21 414,958 +191.3 06/30/2026
Bleichroeder LP 3.09 400,000 +0.0 06/30/2026
Ikarian Capital, LLC 3.06 396,201 +0.0 06/30/2026
Dauntless Investment Group, LLC 2.74 354,208 +343.7 06/30/2026
Stonepine Capital Management Llc 2.67 345,179 +0.0 06/30/2026
Point72 Asset Management, L.P. 1.55 200,300 +0.2 06/30/2026
Ensign Peak Advisors Inc 0.86 110,778 +0.0 06/30/2026
Millennium Management LLC 0.78 101,376 +0.0 06/30/2026

Funds

Funds KZIA
Name Stake (%) Shares Change (%) Date
Exemplar Growth and Income Ser FD 1.23 158,946 +10.4 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?